Genenta Science SpA company info

What does Genenta Science SpA do?
Genenta Science SpA ADR (NASDAQ:GNTA) focuses on pioneering gene therapy technologies targeting and defeating cancer. At its core, the company specializes in developing gene transfer strategies to specifically deliver therapeutic effects to cancerous cells while sparing healthy ones, showcasing a promising revolution in oncologic treatments. Their projects, including the development of Temferon, aim to address unmet medical needs in various cancer types, demonstrating a dedication to improving patient outcomes through innovation. Focused on achieving milestones in cancer gene therapy, Genenta's objectives encompass advancing their pipeline products through clinical trials, expanding their research into new therapeutic areas, and ultimately bringing transformative treatments to patients worldwide. Their endeavors are underscored by a commitment to scientific excellence and compassion for those affected by cancer.
Genenta Science SpA  company media
Company Snapshot

Is Genenta Science SpA a public or private company?

key
Ownership
Public

How many people does Genenta Science SpA employ?

people
Employees
14

What sector is Genenta Science SpA in?

pie chart
Sector
Health Care

Where is the head office for Genenta Science SpA ?

location pin
Head Office
Milan, Italy

What year was Genenta Science SpA founded?

founded flag
Year Founded
2014
What does Genenta Science SpA specialise in?
/Gene Therapy /Cancer Treatment /Monocyte Derivation /Biotechnological Research /Hematopoietic Stem Cells /Drug Development

What are the products and/or services of Genenta Science SpA ?

Overview of Genenta Science SpA offerings
Temferon: A gene therapy product targeting cancer with an initial focus on glioblastoma, employing patient's own cells modified outside the body.
Research in CAR-T technologies: Enhancing Chimeric Antigen Receptor T-cells for better targeting and killing of cancer cells.
Oncolytic virus therapies: Developing viruses that selectively infect and kill cancer cells, while sparing healthy ones.
Cancer immunotherapy: Creating treatments that boost the immune system's natural ability to fight cancer.
Gene editing techniques: Exploring CRISPR and other gene editing tools for precise correction of genetic mutations in cancer.
Stem cell therapy: Investigating the use of stem cells to regenerate damaged tissues and organs in cancer patients.

Who is in the executive team of Genenta Science SpA ?

Genenta Science SpA leadership team
  • Mr. Pierluigi  Paracchi
    Mr. Pierluigi Paracchi
    Vice Chairman of the Board, CEO & GM
  • Dr. Luigi  Naldini M.D., Ph.D.
    Dr. Luigi Naldini M.D., Ph.D.
    Co-Founder & Chairman of the Executive Scientific Board
  • Dr. Bernard Rudolph Gentner M.D., Ph.D.
    Dr. Bernard Rudolph Gentner M.D., Ph.D.
    Co-Founder & Member of the Executive Scientific Board
  • Mr. Richard B. Slansky
    Mr. Richard B. Slansky
    Chief Financial Officer
  • Dr. Carlo  Russo M.D.
    Dr. Carlo Russo M.D.
    Chief Medical Officer & Head of Development
  • Dr. Stefania  Mazzoleni Ph.D.
    Dr. Stefania Mazzoleni Ph.D.
    Director of Program Development
  • Ms. Barbara  Regonini
    Ms. Barbara Regonini
    Director of Finance